close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Global Markets and Technologies for Pandemic Control

  • Published: March 2013
  • |
  • Report Code: PHM042B

REPORT HIGHLIGHTS

The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.

The report provides:

  • An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
  • Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
  • Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
  • Trends based on projected sales through 2017 for new products, including supporting analyses for projections.
  • Comprehensive company profiles of major players.

SAMPLE FIGURE
PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017
(%)
PROJECTED MARKET FOR PANDEMIC INFECTIOUS DISEASE PRODUCTS, BY REGION, 2012 AND 2017
To Contact us, click here  help


Source: BCC Research

Download Report Overview

REPORT SCOPE

INTRODUCTION

REASONS FOR DOING THE STUDY

The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare agencies on guard to avert pending pandemics from these diseases. They have also alerted healthcare professionals to the possibility of the use of viruses and bacteria in bioterrorism threats.

The problem of antimicrobial resistance poses a global threat to the effective treatment of many bacterial diseases. Additionally, the emergence of drug-resistant strains of HIV and hepatitis have jolted the healthcare community out of its relative complacency about the threat of infectious diseases and prompted diagnostic and pharmaceutical manufacturers to bolster their infectious disease pipelines.

Multidrug-resistant tuberculosis is no longer confined to any one country or to those individuals who are co-infected with HIV. A number of multidrug resistant microbes such as methicillin-resistant Staphalococcus auerus (MRSA) and vancomycin-resistant Enterococcus (VRE) that were once found only in hospitals or nursing homes are now active in the community at large.

The rate of HIV infection combined with resistance to existing HIV and acquired immunodeficiency syndrome (AIDS) drugs and the obstacles encountered in developing an AIDS vaccine have resulted in a full-blown pandemic. Further, drug resistance in the treatment of HIV/AIDS necessitates the use of complex dosage protocols with unpleasant side effects that often further debilitate patients.

Solutions to the dilemma of drug resistance involve management approaches on a worldwide scale (such as the implementation of rigorous surveillance of resistant organisms), better education of healthcare workers about appropriate use of antibiotics and closer monitoring of antibiotics used in animal and plant crops.

Combined with these organizational activities is the need for new and effective drugs. New drugs to treat bacterial diseases and HIV/AIDS are being developed, but a new class of drugs to treat bacterial infections has not been developed since 2003, underscoring the need for more development in this area.

SCOPE OF REPORT

This report provides an in-depth look at the emerging pandemic of antibiotic resistance and the established viral pandemic of HIV/AIDS. It also provides historical, epidemiological and market information on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viral diseases that are emerging as health threats because of inadequate or nonexistent preventive and/or therapeutic products to combat them.

Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C. diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics are developed to counteract them. At present, each is problematic, but remains at an epidemic level, primarily within healthcare institutions and nursing facilities. Consequently, these infections are covered descriptively within the report, but are not yet classified as pandemics, nor measured quantitatively as part of the overall market for pandemics.

The report outlines the available preventative and diagnostic products used to combat current and future pandemic infections and projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from an assessment of emerging products and technologies.

The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed.

METHODOLOGY/INFORMATION SOURCES

The data for this report were gathered from primary and secondary sources, including information obtained from industry analysts, manufacturer and company reports, industry trade journals, medical journals and industry associations. Additional information was obtained through the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, The World Health Organization (WHO), the Organisation for Economic Cooperation and Development (OECD), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

Where precise information was not available, projections were made using reasonable assumptions and estimates based on historical data. Market data are based on manufacturers' sales.

INTENDED AUDIENCE

This updated version of the pandemic market and technologies will be a valuable tool for decision makers, marketing personnel and manufacturers in both the diagnostic and pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies and university laboratories will find valuable information on the global diagnostic product and pharmaceutical industries.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations.

BCC ONLINE SERVICES

  • BCC offers an online information retrieval service.  BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders.
  • Subscribe to any of BCC’s many industry newsletters.
  • Read announcements of recently published reports and newly launched newsletters.
  • Register for BCC’s well-known conferences.
  • Request additional information on any BCC product.
  • Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice; nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Download Report Overview

REPORT TOC

download table of contents
Pricing on the website is provided for single users and 2-5 users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at (+1)781-489-7301 or send an email to information@bccresearch.com
  Title/Chapter Name Pages Price
Global Markets and Technologies for Pandemic Control 172 $6650
Chapter- 1: INTRODUCTION - Complimentary 3 $0
  Show Details
Chapter- 2: SUMMARY 3 $250
  Show Details
Chapter- 3: OVERVIEW 16 $928
  Show Details
Chapter- 4: VACCINES, DIAGNOSTIC TESTING, AND PHARMACEUTICAL MARKETS FOR INFECTIOUS DISEASES 27 $1566
  Show Details
Chapter- 5: DISEASE OVERVIEW 24 $1392
  Show Details
Chapter- 6: VIRAL PANDEMIC THREATS AND TREATMENTS 21 $1218
  Show Details
Chapter- 7: BACTERIAL PANDEMIC THREATS AND TREATMENTS 17 $986
  Show Details
Chapter- 8: PARASITIC PANDEMIC THREATS AND TREATMENTS 11 $638
  Show Details
Chapter- 9: REGULATIONS 5 $290
  Show Details
Chapter- 10: PHARMACEUTICAL TREATMENT PIPELINE 10 $580
  Show Details
Chapter- 11: PATENT ANALYSIS 11 $638
  Show Details
Chapter- 12: COMPANY DIRECTORY 24 $1392
  Show Details
 
  List of Tables
  List of Figures
Recommended combos for Forecast Model
+

BCC Research Report

Price: $6650

=

Total Price: $12150

Combo Price: $9500

Discount will be applied automatically after you will add the forecast model and any report to your cart.

 
Select License type:
buy now
downlaod report overview
Want to find out more
about this report?
request more info
Get Notified
on all the latest research reports
Subscribe

Choose your License

loading animation for AJAX calls